Skip to main content

Table 2 Post-Ipi Systemic Txs.

From: Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience

Post-Ipi
Systemic Tx
# pts # pts achieving ≥1yr disease control*
Cytotoxic Therapy 11/80 (14%) 5/10 (50%)
Anti-PD-1/PD-L1 16/80 (20%) 11/15 (73%)
BRAF inhibitor 10/80 (13%) 7/9 (78%)
Ipi re-induction 18/80 (23%) 5/16 (31%)
Other clinical trial 13/80 (16%) 1/13 (8%)
  1. *pts with ongoing disease control and <1yr follow up excluded